Published On: Mon, Jul 17th, 2017

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Broker Views On Wall Street


A number of investment brokers have recently updated their price targets on shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Most recent broker ratings

07/10/2017 – Integra LifeSciences Holdings Corporation had its “overweight” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 65 price target on the stock.

06/23/2017 – Integra LifeSciences Holdings Corporation had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 60 price target on the stock.

06/07/2017 – Integra LifeSciences Holdings Corporation had its “buy” rating reiterated by analysts at UBS. They now have a USD 60 price target on the stock.

05/31/2017 – Integra LifeSciences Holdings Corporation had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 58 price target on the stock.

05/02/2017 – Integra LifeSciences Holdings Corporation had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 48 price target on the stock.

03/22/2017 – Integra LifeSciences Holdings Corporation had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 47 price target on the stock.

01/12/2017 – Integra LifeSciences Holdings Corporation had its “equal-weight” rating reiterated by analysts at Barclays. They now have a USD 42 price target on the stock.

01/06/2017 – Integra LifeSciences Holdings Corporation was upgraded to “market outperform” by analysts at JMP Securities. They now have a USD 50 price target on the stock.

10/28/2016 – Integra LifeSciences Holdings Corporation was upgraded to “buy” by analysts at Lake Street. They now have a USD 92 price target on the stock.

09/23/2016 – Integra LifeSciences Holdings Corporation had its “buy” rating reiterated by analysts at Argus. They now have a USD 105 price target on the stock.

07/13/2016 – Integra LifeSciences Holdings Corporation had its “overweight” rating reiterated by analysts at JP Morgan.

11/12/2015 – Citigroup began new coverage on Integra LifeSciences Holdings Corporation giving the company a “buy” rating. They now have a USD 75 price target on the stock.

09/21/2015 – Integra LifeSciences Holdings Corporation was upgraded to “buy” by analysts at Bank of America Merrill Lynch. They now have a USD 79 price target on the stock.

07/29/2015 – Integra LifeSciences Holdings Corporation was upgraded to “outperform” by analysts at Raymond James.

05/05/2015 – Integra LifeSciences Holdings Corporation was upgraded to “buy” by analysts at Zacks. They now have a USD 73 price target on the stock.

The share price of Integra LifeSciences Holdings Corporation (NASDAQ:IART) was up +0.94% during the last day of trading, with a day high of 55.24. 405279 shares were traded during the last session.

The stock’s 50 day moving average is 50.84 and its 200 day moving average is 49.46. The stock’s market capitalization is 4.16B. Integra LifeSciences Holdings Corporation has a 52-week low of 37.71 and a 52-week high of 55.24.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.